Clients

NeuBase Therapeutics, Inc.

Company Snapshot: NeuBase Therapeutics, Inc.

NBSE
Last Change Volume High Low

Company Overview

NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Client News

  1. Aug 11 2022 NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
  2. Aug 11 2022 NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
  3. Jun 29 2022 NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
  4. Jun 1 2022 NeuBase to Participate at the Jefferies Healthcare Conference